FREE

White Paper Highlights Attributes of CBC

Therapeutic attributes of CBC highlighted in white paper. InMed Pharmaceuticals’ commercial subsidiary BayMedica released a white paper, which collates a curated collection of scientific research on the physiological and potential therapeutic effects of cannabichromene (CBC). CBC is BayMedica’s lead product sold to the health & wellness sector. The BayMedica white paper can be accessed in our full report by accessing the link below. CBC demonstrates potent anti-inflammatory effects. Since the discovery of the endocannabinoid system (ES) in 1988, there has been mounting research into the interaction of cannabinoids with ES receptors, which regulate critical human functions, such as temperature, appetite, blood sugar, sleep, memory, emotional processing, pain, and inflammatory and immune responses. Scientific research demonstrates that CBC acts as an agonist of a number of ES receptors but has been shown to be the most potent agonist of TRPA1 receptors, which are primarily found in the peripheral sensory cells, regulating pain, cold sensation, and hearing. CBC’s entourage effect. What sets CBC apart most from other cannabinoids is that research has demonstrated evidence of its synergistic effect when combined with other cannabinoids, known as the entourage effect. The entourage effect describes the complementary effects of multiple compounds that might lead to potentially better therapeutic outcomes than a single compound on its own. Several studies have demonstrated CBC’s synergistic effects with THC, CBD, and others. CBC’s growth potential. BayMedica’s revenue growth profile in the last three quarters offers compelling evidence that select rare cannabinoids, led by its lead product CBC, are starting to make their mark as ingredients of growing importance in health & wellness products. While global CBC sales totaled $1.7 million in 2022, up from virtually zero in 2020 and $0.5 million in 2021, sales for the more established rare cannabinoids such as CBN and CBG were $187 million and $55 million, respectively. These figures serve to highlight the growth potential of CBC, which is all more realizable amid growing awareness of its therapeutic properties backed up by a body of scientific literature. Moreover, although InMed’s rare cannabinoid business has nothing to do with the cannabis plant, the possible rescheduling of cannabis from a Schedule 1 substance to Schedule 3 will likely add fuel to the vigorous demand for cannabinoids from the health & wellness sector.